[go: up one dir, main page]

AR091349A1 - Formulacion oral - Google Patents

Formulacion oral

Info

Publication number
AR091349A1
AR091349A1 ARP130101449A AR091349A1 AR 091349 A1 AR091349 A1 AR 091349A1 AR P130101449 A ARP130101449 A AR P130101449A AR 091349 A1 AR091349 A1 AR 091349A1
Authority
AR
Argentina
Prior art keywords
oral formulation
medicament
pululane
maltodextrin
salts
Prior art date
Application number
Other languages
English (en)
Inventor
Takeda Chikako
Kurahashi Nobuyuki
Oka Yoshikazu
Iwamoto Taro
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR091349A1 publication Critical patent/AR091349A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Reivindicación 1: Una formulación oral caracterizado porque comprende un medicamento, alcohol de azúcar, uno o varios tipos de polisacáridos hidrofílicos seleccionados del grupo que consiste en goma arábiga, pululano y maltodextrina, un agente gelante y agua. Reivindicación 11: La formulación oral de acuerdo con cualquiera de las reivindicaciones 1 - 10, caracterizado porque el medicamento es un medicamento básico. Reivindicación 12: La formulación oral de acuerdo con la reivindicación 11, caracterizado porque el medicamento básico es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin-2-ona o una de sus sales o aripiprazol o una de sus sales. Reivindicación 15: Un sustrato para formulación oral, caracterizado porque comprende alcohol de azúcar, uno o varios tipos de polisacáridos hidrofílicos seleccionados del grupo que consiste en acacia, pululano y maltodextrina, un agente gelante y agua.
ARP130101449 2012-04-30 2013-04-29 Formulacion oral AR091349A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261640474P 2012-04-30 2012-04-30
US201361783163P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
AR091349A1 true AR091349A1 (es) 2015-01-28

Family

ID=48483123

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101449 AR091349A1 (es) 2012-04-30 2013-04-29 Formulacion oral

Country Status (21)

Country Link
US (3) US20150126521A1 (es)
EP (1) EP2844232A1 (es)
JP (1) JP6360795B2 (es)
KR (1) KR20150003898A (es)
CN (1) CN104271120A (es)
AR (1) AR091349A1 (es)
AU (1) AU2013255256B2 (es)
BR (1) BR112014026879A2 (es)
CA (1) CA2872004A1 (es)
CO (1) CO7151505A2 (es)
EA (1) EA026187B1 (es)
HK (1) HK1207290A1 (es)
IL (1) IL235111A0 (es)
IN (1) IN2014DN09091A (es)
MX (1) MX2014013155A (es)
NZ (1) NZ630029A (es)
PH (1) PH12014502323A1 (es)
SG (2) SG11201406261QA (es)
TW (1) TWI594765B (es)
WO (1) WO2013165021A1 (es)
ZA (1) ZA201408114B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
US11654108B1 (en) 2022-05-02 2023-05-23 Medicated Chews, Llc Sennoside medicated chews

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517886B1 (en) * 1997-06-24 2003-02-11 Biovail Corporation International Positive hydration method of preparing confectionery and the resulting product
AUPQ970300A0 (en) * 2000-08-29 2000-09-21 Massa Nominees Pty Ltd Advanced wireless network
FR2822644B1 (fr) * 2001-03-30 2005-03-11 Roquette Freres Confiserie sans sucre
JP2004099558A (ja) * 2002-09-11 2004-04-02 Medorekkusu:Kk 医薬用ゼリー組成物
JP4547994B2 (ja) * 2004-06-02 2010-09-22 救急薬品工業株式会社 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
US20100093875A1 (en) * 2006-10-25 2010-04-15 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation prevented from caking
CA2682752C (en) * 2007-04-05 2015-07-07 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
WO2010116385A2 (en) * 2009-04-08 2010-10-14 Rubicon Research Private Limited Pharmaceutical compositions for alleviating unpleasant taste
KR101074271B1 (ko) * 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
US20110139164A1 (en) * 2009-12-15 2011-06-16 R. J. Reynolds Tobacco Company Tobacco Product And Method For Manufacture
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
JP5611672B2 (ja) * 2010-05-28 2014-10-22 ゼリア新薬工業株式会社 経口ゼリー剤
NZ603076A (en) * 2010-08-24 2014-12-24 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyril derivative and silicone oil and/or silicone oil derivative
GB201016900D0 (en) * 2010-10-06 2010-11-17 Probio Asa Emulsion
WO2014104989A1 (en) * 2011-12-27 2014-07-03 Mahmut Bilgic Pharmaceutical compositions comprising aripiprazole

Also Published As

Publication number Publication date
AU2013255256B2 (en) 2017-09-07
TW201347773A (zh) 2013-12-01
EP2844232A1 (en) 2015-03-11
CN104271120A (zh) 2015-01-07
HK1207290A1 (en) 2016-01-29
SG10201608954UA (en) 2016-12-29
AU2013255256A2 (en) 2014-11-13
CO7151505A2 (es) 2014-12-29
NZ630029A (en) 2016-05-27
SG11201406261QA (en) 2014-11-27
US20170202833A1 (en) 2017-07-20
EA026187B1 (ru) 2017-03-31
JP2015515959A (ja) 2015-06-04
MX2014013155A (es) 2015-05-08
JP6360795B2 (ja) 2018-07-18
US20180055840A1 (en) 2018-03-01
TWI594765B (zh) 2017-08-11
ZA201408114B (en) 2016-08-31
CA2872004A1 (en) 2013-11-07
WO2013165021A1 (en) 2013-11-07
IL235111A0 (en) 2014-12-31
BR112014026879A2 (pt) 2017-06-27
US20150126521A1 (en) 2015-05-07
IN2014DN09091A (es) 2015-05-22
PH12014502323A1 (en) 2015-01-12
EA201491995A1 (ru) 2015-02-27
KR20150003898A (ko) 2015-01-09
AU2013255256A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
CL2015003442A1 (es) Derivados heterociclicos
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
AR092180A1 (es) Metodo y sistema para dispensar una composicion
MX2021010033A (es) Composiciones microencapsuladas de cannabinoides.
MX2019012979A (es) Composiciones para el cuidado bucal.
MX387604B (es) Formulaciones cannabinoides estables.
DOP2016000253A (es) Nuevos compuestos
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
CL2016000143A1 (es) Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel
CL2014002282A1 (es) Anticuerpos contra la metaloproteinasa de la matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que la contiene; y sus usos.
MX376628B (es) Composiciones para el cuidado bucal.
CL2014002975A1 (es) Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
HRP20181362T1 (hr) Kompenzacija za farmaceutsku, nutritivnu ili kozmetičku upotrebu na bazi flavonoida koja ima pojačano antioksidativno djelovanje
MX2017000076A (es) Macromoleculas estrellas compatibles con tensoactivos.
AR089486A1 (es) PREPARACION FARMACEUTICA QUE COMPRENDE b-CICLODEXTRINA SUSTITUIDA
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
MX376262B (es) Composiciones para el cuidado bucal con alto contenido de agua y micro resistencia.
EP2968195A4 (en) PHARMACEUTICAL FORMULATION WITH GLYCOSAMINOGLYCAN
AR091349A1 (es) Formulacion oral
BR112017019750A2 (pt) processo para preparação de uma forma cristalina de menaquinol, forma cristalina de menaquinol, processo para preparação de uma forma sólida do menaquinol, composição farmacêutica ou nutracêutica e uso da forma cristalina de menaquinol
BR112013019924A2 (pt) composições para cuidado oral
MX381192B (es) Una particula antimicrobiana y composiciones de la misma.
CL2017000117A1 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt

Legal Events

Date Code Title Description
FB Suspension of granting procedure